Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial.
Guozhen YangXiaodong SuYuanheng HuangGuangyu LuoZhiqiang WangPeiqiang CaiYating ZhengTing BeiMengli HuangYuezong BaiHaoqiang HeJin XiangMuyan CaiJiudi ZhongQiyu GuoXu ZhangPublished in: Journal of translational medicine (2023)
It seems probable that intensive cycles of neoadjuvant camrelizumab plus nab-paclitaxel and capecitabine increased tumor regression and improved survival outcomes. Randomized controlled trials with larger sample sizes and longer follow-up periods are needed to validate these findings. Trial registration Chinese Clinical Trial Registry, ChiCTR2000029807, Registered February 14, 2020, https://www.chictr.org.cn/showproj.aspx?proj=49459 .
Keyphrases
- locally advanced
- clinical trial
- rectal cancer
- phase iii
- neoadjuvant chemotherapy
- phase ii
- open label
- study protocol
- squamous cell carcinoma
- randomized controlled trial
- phase ii study
- radiation therapy
- lymph node metastasis
- double blind
- placebo controlled
- advanced non small cell lung cancer
- systematic review
- lymph node
- tyrosine kinase